UBS Maintains Buy on DexCom, Raises Price Target to $163
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Buy rating on DexCom (NASDAQ:DXCM) and raises the price target from $153 to $163.
April 10, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Danielle Antalffy has maintained a Buy rating on DexCom and increased the price target from $153 to $163.
The increase in DexCom's price target by a reputable analyst suggests a positive outlook on the company's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100